Clinical Trial » Agency » Boehringer Ingelheim Pharmaceuticals

Boehringer Ingelheim Pharmaceuticals

Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease
31 May 2009
This is a double blind, placebo-controlled clinical trial of 15 months duration designed to examine early Mirapex (pramipexole) treatment vs. delayed Mirapex (pramipexole) treatment in ... 
First Presentation of Parkinson Disease Patients to Neurologist
02 Dec 2008
In this study information is gathered about the treatment of Parkinson patients who present themselves in a neurological practice for the first time ... 
Non-Interventional Observational Study on WHO-5 Questionnaire Application in Parkinson's Disease
11 Sep 2008
To assess the predictive value of sequential administration of WHO-5 and MDI (Major Depression Inventory) for the clinical management of Parkinson Disease (PD) patients by - ... 
Non-Motor Symptoms (Depressive Symptoms) of Parkinson's Disease and Their Course Under Pramipexole Treatment
30 Mar 2008
The objective of this PMS study is the evaluation of depressive symptoms measured with UPDRS Part I (mentation, behavior and mood) and with HADSD under pramipexole treatment in early and ... 
Impulse Control Disorders in Parkinson's Patients Treated With Pramipexole and Other Agents (DOMINION Study)
04 Feb 2008
The purpose is to explore the frequency of impulse control disorders in Parkinson's patients treated with different Parkinson's medications. ... 
Survey on Parkinson's Disease (PD) Patients With Depressive Symptoms
30 Jan 2008
The primary objective of this investigation is to conduct a 12-week prospective survey in PD patients with depressive symptoms treated with BI Sifrol Tablets (hereinafter referred to as this drug) in ... 
Special Survey on PD Patients With Renal Dysfunction
30 Jan 2008
Since BI-Sifrol Tablets (pramipexole tablets) are renally excreted, the object of the present survey is to collect safety and effectiveness information targeting patients who have both Parkinson's ... 
Special Survey on PD Patients With Renal Dysfunction
30 Jan 2008
Since BI-Sifrol Tablets (pramipexole tablets) are renally excreted, the object of the present survey is to collect safety and effectiveness information targeting patients who have both Parkinson's ... 
Special Survey on PD Patients Without Concomitant Use of L-Dopa
30 Jan 2008
The survey is conducted to collect safety and effectiveness information in Parkinson's Disease patients treated with Pramipexole without concomitant L-Dopa supplementation in the daily clinical ... 
Long-Term Safety Study of Open-Label Pramipexole Extended Release (ER) in Patients With Early Parkinson´s Disease (PD).
14 Jan 2008
The general aim of this study is to obtain long-term safety and tolerability data on pramipexole ER, in daily doses from 0.375mg to 4.5mg q.d, in patients who have previously completed a pramipexole ... 
Syndicate content